Antibody development platform
Next Gen. CAR-T
Explore the Latest Carsgen News
CARsgen Therapeutics Opens CAR T-cell Manufacturing Facility in Shanghai
Dr. Li Zonghai gave speech at CAR-T TCR 2016 Annual Summit
CARsgen Therapeutics Completes $30 Million Series B Financing
CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute and to Develop Novel CAR-T ...
CARsgen Completes Series A Financing
Adoptive Immunotherapy using T Lymphocytes Redirected to Glypican-3 for the Treatment of Lung ...
Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.